The aim of first study was to evaluate the effect of supplementation with probiotic strains Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032 on triglyceride (TG) and apolipoprotein A-V (apoA-V) levels. A randomized, double-blinded, placebo-controlled stud...
The aim of first study was to evaluate the effect of supplementation with probiotic strains Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032 on triglyceride (TG) and apolipoprotein A-V (apoA-V) levels. A randomized, double-blinded, placebo-controlled study was conducted on 128 non-diabetic subjects with hypertriglyceridemia. Over a 12-week test period, the probiotic group consumed 2 g/day of a powdered supplement containing L. curvatus HY7601 and L. plantarum KY1032, while the placebo group consumed a powder lacking probiotics. After the treatment, the probiotic group showed an 18.3 % (P<0.001) reduction in TG and increases of 21.1 % (P=0.001) and 15.6 % (P<0.001) in apoA-V and LDL particle size, respectively. The probiotic group had a significant reduction in TG (P=0.040) and increases in plasma apoA-V (P=0.003) and LDL particle size (PC genotype. The consumption of two probiotic strains for 12 weeks reduced TG and increased in apoA-V and LDL particle size in hypertriglyceridemic subjects. This effect was more pronounced in subjects with higher levels of fasting TG, regardless of their APOA5 -1131T>C genotype.The aim of second study was to evaluate the TG-lowering effect of the consumption of dual probiotic strains containing L. curvatus HY7601 and L. plantarum KY 1032 on fasting plasma metabolites. A randomized, double-blind, placebo-controlled study was conducted on 92 nondiabetic and hypertriglyceridemic subjects. Over a 12 week test period, the probiotic group consumed a daily 2 g powder of a dual probiotic strains containing 0.5 x 1010 colony-forming units (cfu) of L. curvatus HY7601 and 0.5 x 1010 cfu L. plantarum KY1032, while the placebo group consumed the same product without probiotics for 12 weeks. Fasting plasma metabolites were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group presented a reduction of 20 % (P=0.001) in serum TG and increases of 25 % (P=0.001) in apoA-V. At the 12-week follow-up, the following 12 plasma metabolites in the probiotic group were greatly reduced than those in the placebo group - palmitoleamide, palmitic amide, oleamide, lysophosphatidylcholine (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (△) of TG negatively correlated with △ apoA-V, which positively correlated with △ FFA. Additionally, △ FFA strongly and positively correlated with △ lysoPCs in the probiotic group but not in the placebo group. The TG-lowering effects of probiotic supplementation partly through elevated apoA-V in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites; fatty acid primary amides and lysoPCs.
The aim of first study was to evaluate the effect of supplementation with probiotic strains Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032 on triglyceride (TG) and apolipoprotein A-V (apoA-V) levels. A randomized, double-blinded, placebo-controlled study was conducted on 128 non-diabetic subjects with hypertriglyceridemia. Over a 12-week test period, the probiotic group consumed 2 g/day of a powdered supplement containing L. curvatus HY7601 and L. plantarum KY1032, while the placebo group consumed a powder lacking probiotics. After the treatment, the probiotic group showed an 18.3 % (P<0.001) reduction in TG and increases of 21.1 % (P=0.001) and 15.6 % (P<0.001) in apoA-V and LDL particle size, respectively. The probiotic group had a significant reduction in TG (P=0.040) and increases in plasma apoA-V (P=0.003) and LDL particle size (PC genotype. The consumption of two probiotic strains for 12 weeks reduced TG and increased in apoA-V and LDL particle size in hypertriglyceridemic subjects. This effect was more pronounced in subjects with higher levels of fasting TG, regardless of their APOA5 -1131T>C genotype.The aim of second study was to evaluate the TG-lowering effect of the consumption of dual probiotic strains containing L. curvatus HY7601 and L. plantarum KY 1032 on fasting plasma metabolites. A randomized, double-blind, placebo-controlled study was conducted on 92 nondiabetic and hypertriglyceridemic subjects. Over a 12 week test period, the probiotic group consumed a daily 2 g powder of a dual probiotic strains containing 0.5 x 1010 colony-forming units (cfu) of L. curvatus HY7601 and 0.5 x 1010 cfu L. plantarum KY1032, while the placebo group consumed the same product without probiotics for 12 weeks. Fasting plasma metabolites were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group presented a reduction of 20 % (P=0.001) in serum TG and increases of 25 % (P=0.001) in apoA-V. At the 12-week follow-up, the following 12 plasma metabolites in the probiotic group were greatly reduced than those in the placebo group - palmitoleamide, palmitic amide, oleamide, lysophosphatidylcholine (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (△) of TG negatively correlated with △ apoA-V, which positively correlated with △ FFA. Additionally, △ FFA strongly and positively correlated with △ lysoPCs in the probiotic group but not in the placebo group. The TG-lowering effects of probiotic supplementation partly through elevated apoA-V in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites; fatty acid primary amides and lysoPCs.
주제어
#락토바실러스 커바터스 HY7601
#락토바실러스 플란타룸 KY1032
#중성지방
#아포리포단백질 A-V
#대사체
#비당뇨
#고중성지방혈증
#Lactobacillus curvatus HY7601
#Lactobacillus plantarum KY1032
#triglycerides
#apolipoprotein A-V
#metabolites
#nondiabetic
#hypertriglyceridemic
※ AI-Helper는 부적절한 답변을 할 수 있습니다.